Publication:
Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients

dc.contributor.buuauthorArslan, Murat
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorDemiray, Mutlu
dc.contributor.buuauthorErcan, İlker
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorÖzkan, Atilla
dc.contributor.buuauthorMananoğlu, Osman
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentHematoloji Ana Bilim Dalı
dc.contributor.departmentBiyoistatistik Ana Bilim Dalı
dc.contributor.departmentTıbbi Onkoloji Ana Bilim Dalı
dc.contributor.orcid0000-0002-9732-5340
dc.contributor.orcid0000-0003-2501-3097
dc.contributor.orcid0000-0002-2382-290X
dc.contributor.researcheridAAJ-1027-2021
dc.contributor.researcheridM-8060-2019
dc.contributor.scopusid57197925370
dc.contributor.scopusid6603942124
dc.contributor.scopusid7006207332
dc.contributor.scopusid6603631569
dc.contributor.scopusid6603789069
dc.contributor.scopusid55881548500
dc.contributor.scopusid7201813027
dc.contributor.scopusid9250698600
dc.contributor.scopusid6602587152
dc.date.accessioned2022-03-15T05:56:08Z
dc.date.available2022-03-15T05:56:08Z
dc.date.issued2005
dc.description.abstractThere are conflicting data about the effects of cisplatin on erythropoietin (EPO) response to anemia. Aim of our study was to investigate whether endogenous EPO response to anemia in cisplatin treated patients was insufficient in comparison to the anemic chemotherapy-naive cancer patients and non cancer patients with iron deficiency anemia. Patients who had hemoglobin (Hb) levels of less than 110 g/l were included in the study. Fifteen chemotherapy-naive cancer patients were enrolled in Group A. Group B consisted of 15 patients who had been treated with three cycles of cisplatin chemotherapy and then became anemic and in Group C were included 15 patients who had iron deficiency anemia, without any malignancy. The mean Hb values were not different between all groups (102.8 +/- 39.8 g/l, 103.1 +/- 2.5 g/l and 99.3 +/- 3.6 g/l in Group A, Group B and Group C, respectively). However, EPO levels were found to be significantly lower in Group A and Group B than Group C (29.63 +/- 9.09 mU/ml, 20.87 +/- 2.43 mU/ml and 85.38 +/- 25.72 mU/ml, respectively; p=0.017 Group A vs. Group C, p=0.005 Group B vs. Group C). No significant difference was found between Group A and B (p=0.917). Opposite the iron deficiency anemia, cancer anemia is associated with an inadequate EPO response to anemia and administration of cisplatin does not lead to it further deterioration.
dc.identifier.citationArslan, M. vd. (2005). "Comparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients". Neoplasma, 52(1), 43-45.
dc.identifier.endpage45
dc.identifier.issn0028-2685
dc.identifier.issue1
dc.identifier.pubmed15739025
dc.identifier.scopus2-s2.0-14744270022
dc.identifier.startpage43
dc.identifier.urihttp://hdl.handle.net/11452/25012
dc.identifier.volume52
dc.identifier.wos000227291100007
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherAepress Sro
dc.relation.journalNeoplasma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOncology
dc.subjectAnemia
dc.subjectErythropoietin
dc.subjectCisplatin
dc.subjectCancer
dc.subject.emtreeAntineoplastic agent
dc.subject.emtreeCisplatin
dc.subject.emtreeCyanocobalamin
dc.subject.emtreeErythropoietin
dc.subject.emtreeFerritin
dc.subject.emtreeFolic acid
dc.subject.emtreeHemoglobin
dc.subject.emtreeAdult
dc.subject.emtreeAnemia
dc.subject.emtreeArticle
dc.subject.emtreeAutoanalysis
dc.subject.emtreeBlood level
dc.subject.emtreeCancer chemotherapy
dc.subject.emtreeCancer patient
dc.subject.emtreeChemoluminescence
dc.subject.emtreeClinical article
dc.subject.emtreeControlled study
dc.subject.emtreeEsophagus cancer
dc.subject.emtreeFemale
dc.subject.emtreeHematological parameters
dc.subject.emtreeHemoglobin determination
dc.subject.emtreeHuman
dc.subject.emtreeIron deficiency anemia
dc.subject.emtreeLaboratory test
dc.subject.emtreeLarynx cancer
dc.subject.emtreeLung cancer
dc.subject.emtreeMale
dc.subject.emtreeNasopharynx cancer
dc.subject.emtreeSerum
dc.subject.emtreeSkin cancer
dc.subject.emtreeSolid tumor
dc.subject.emtreeStomach cancer
dc.subject.emtreeTreatment outcome
dc.subject.scopusErythropoietin Receptors; Antianemic Agent; Anemias
dc.subject.wosOncology
dc.titleComparison of the serum erythropoietin levels in chemotherapy-naive and cisplatin-treated cancer patients
dc.typeArticle
dc.wos.quartileQ4
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıbbi Onkoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Hematoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: